Assessment of anti-donor T cell proliferation and cytotoxic T lymphocyte-mediated lympholysis in living donor kidney transplant patients

Methods in Molecular Biology

Volumn 1213, Issue , 2014, Pages 355-364

  Rakha, Aruna ^a   Todeschini, Marta ^a   Casiraghi, Federica ^a  

^a NONE

Author keywords

51Cr release assay; CFSE; Cytotoxic T cell mediated lympholysis; Immunomonitoring; Kidney transplant recipients; Mesenchymal stromal cells; T cell proliferation

Indexed keywords

CELL MEDIATED LYMPHOLYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DILUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; CYTOTOXICITY; FLOW CYTOMETRY; GRAFT REJECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; MIXED LYMPHOCYTE CULTURE;

CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84929503110     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1453-1_29     Document Type: Chapter

References (13)

1. Casiraghi F, Perico N, Remuzzi G (2013) Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant 18:51–58.
2. English K, Wood KJ (2013) Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb Perspect Med 3:a015560.
3. Duffy MM, Ritter T, Ceredig R et al (2011) Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2:34.
4. English K (2013) Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 91:19–26.
5. Le Blanc K, Mougiakakos D (2012) Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 12:383–396.
6. Krampera M, Galipeau J, Shi Y et al (2013) Immunological characterization of multipotent mesenchymal stromal cells—the International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15:1054–1061.
7. Perico N, Casiraghi F, Introna M et al (2011) Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 6:412–422.
8. Casiraghi F, Azzollini N, Todeschini M et al (2012) Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 12:2373–2383.
9. Koch M, Lehnhardt A, Hu X et al (2013) Isogeneic MSC application in a rat model of acute renal allograft rejection modulates immune response but does not prolong allograft survival. Transpl Immunol. doi:10.1016/j.trim.2013.08.004.
10. Tan J, Wu W, Xu X et al (2012) Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307: 1169–1177.
11. Reinders ME, de Fijter JW, Roelofs H et al (2013) Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2:107–111.
12. Perico N, Casiraghi F, Gotti E et al (2013) Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int 26:867–878.
13. Peng Y, Ke M, Xu L et al (2013) Donorderived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 95:161–168.